Merck, 559397-1ML, SB 202190

General description
A potent and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (IC₅₀ = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC₅₀ = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to block LDL expression in Hep52 cells.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
P38β
Product competes with ATP.
Reversible: yes
Target Ki: 350 nM against the kinase activity of p38β; 280 nM against p38 phosphorylation of activating transcription factor 2 (ATF-2)
Packaging
Packaged under inert gas
Please refer to vial label for lot-specific concentration.
Physical form
A 1 mg/ml solution of SB 202190 (Cat. No. 559388) in anhydrous DMSO.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Other Notes
Ajizian, S.J., et al. 1999. J. Infect. Dis.179, 939.
Singh, R.P., et al. 1999. J. Biol. Chem.274, 19593.
Wang, S.W., et al. 1999. Inflamm. Res.48, 533.
Gallagher, T.F., et al. 1997. Bioorg. Med. Chem.5, 49.
Jiang, Y., et al. 1996. J. Biol. Chem.271, 17920.
Kramer, R.M., et al. 1996. J. Biol. Chem.271, 27723.
Li, Z., et al. 1996. Biochem. Biophys. Res. Commun.228, 334.
Lee, L.C., et al. 1994. Nature372, 739.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Irritant (B)